TR200103409T2 - Glukoz çıkışı arttırıcıları olarak naftalen üreleri. - Google Patents

Glukoz çıkışı arttırıcıları olarak naftalen üreleri.

Info

Publication number
TR200103409T2
TR200103409T2 TR2001/03409T TR200103409T TR200103409T2 TR 200103409 T2 TR200103409 T2 TR 200103409T2 TR 2001/03409 T TR2001/03409 T TR 2001/03409T TR 200103409 T TR200103409 T TR 200103409T TR 200103409 T2 TR200103409 T2 TR 200103409T2
Authority
TR
Turkey
Prior art keywords
enhancers
glucose output
useful
ureas
naphthalene
Prior art date
Application number
TR2001/03409T
Other languages
English (en)
Inventor
Spevak Wayne
T. Lum Robert
Shi Songyuan
Manchem Prasad
R. Kozlowski Michael
R. Schow Steven
Original Assignee
Telik, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik, Inc. filed Critical Telik, Inc.
Publication of TR200103409T2 publication Critical patent/TR200103409T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/51—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/18—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/30—Isothioureas
    • C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4021—Esters of aromatic acids (P-C aromatic linkage)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Formül (I)'e ait bilesikler veya bunlarin farmasötik açidan kabul gören bir tuzu,tekli bir stereoizomer veya stereoizomeler karisimi olarak, diaftilüreler ile hiperglisemiye, özellikle de Tip II diyabetlere bagli durumlarin tedavisinde faydalidir.Bu bilesikler,insülin alicisinin kinaz aktivitesinin uyarilmasinda,insülin alicisinin aktive edilmesinde ve glukoz aliminin uyarilmasinda yararlidir.Antidiyabetik bilesikler ihtiva eden farmasötik komposizyonlar da ortaya konulmustur.
TR2001/03409T 1999-05-26 2000-05-25 Glukoz çıkışı arttırıcıları olarak naftalen üreleri. TR200103409T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13612899P 1999-05-26 1999-05-26

Publications (1)

Publication Number Publication Date
TR200103409T2 true TR200103409T2 (tr) 2002-05-21

Family

ID=22471427

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03409T TR200103409T2 (tr) 1999-05-26 2000-05-25 Glukoz çıkışı arttırıcıları olarak naftalen üreleri.

Country Status (26)

Country Link
US (2) US6458998B1 (tr)
EP (1) EP1181271B1 (tr)
JP (1) JP2003500381A (tr)
KR (1) KR100746870B1 (tr)
CN (1) CN1364156A (tr)
AR (1) AR024109A1 (tr)
AT (1) ATE287394T1 (tr)
AU (1) AU776438C (tr)
BR (1) BR0011550A (tr)
CA (1) CA2374225A1 (tr)
CZ (1) CZ20014153A3 (tr)
DE (1) DE60017554T2 (tr)
EA (1) EA006763B1 (tr)
ES (1) ES2233386T3 (tr)
HK (1) HK1046399A1 (tr)
HU (1) HUP0201306A3 (tr)
IL (2) IL146576A0 (tr)
MX (1) MXPA01012079A (tr)
NO (1) NO20015713L (tr)
NZ (1) NZ515743A (tr)
PL (1) PL352631A1 (tr)
TR (1) TR200103409T2 (tr)
TW (1) TWI234557B (tr)
UA (1) UA73738C2 (tr)
WO (1) WO2000071506A2 (tr)
ZA (1) ZA200109641B (tr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7058589B1 (en) * 1998-12-17 2006-06-06 Iex Corporation Method and system for employee work scheduling
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6897237B2 (en) 2000-04-28 2005-05-24 Shionogi & Co. Ltd. MMP-12 inhibitors
ITTO20010950A1 (it) * 2000-10-11 2003-04-09 Telik Inc Attivatori di recettori di insulina per il trattamento di disturbi metabolici in esseri umani che risultano dal trattamento di infezioni da
US6528037B2 (en) 2000-10-11 2003-03-04 Telik, Inc. Method for determining whether a compound is an insulin receptor kinase activator
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
JP4411275B2 (ja) 2002-10-21 2010-02-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換テトラリンおよびインダンそしてこれらの使用
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
DE602004010407T2 (de) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
BRPI0610034A2 (pt) 2005-04-28 2011-10-18 Ajinomoto Kk composto, agente de icremento do transporte de açúcar, agente hipoglicêmico, agente para prevenção e/ou tratamento de uma doença, medicamento, composição farmacêutica , uso do composto, e, método de preparação para o composto
AU2012200933B2 (en) * 2005-06-22 2015-04-30 Plexxikon, Inc. Pyrrolo [2, 3-B] pyridine derivatives as protein kinase inhibitors
EP1893612B1 (en) * 2005-06-22 2011-08-03 Plexxikon, Inc. Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors
WO2007030618A2 (en) 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of voltage gated ion channels
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SG173178A1 (en) 2009-04-03 2011-09-29 Hoffmann La Roche Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
NZ629615A (en) 2009-11-06 2016-01-29 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH488212A (de) * 1967-09-01 1970-03-31 Ciba Geigy Photographisches Material
CA985675A (en) * 1971-04-07 1976-03-16 Ciba-Geigy Ag Azo dyestuffs, their manufacture and use
US4118232A (en) * 1971-04-07 1978-10-03 Ciba-Geigy Ag Photographic material containing sulphonic acid group containing disazo dyestuffs
US4051176A (en) * 1976-05-10 1977-09-27 American Cyanamid Company Ureidophenylenebis(carbonylimino)dinaphthalenetrisulfonic acid compounds
US4129591A (en) * 1976-10-27 1978-12-12 American Cyanamid Company Ureida-phenylenebis(substituted imino)multianionic substituted dinaphthalene sulfonic acids and salts
US4102917A (en) * 1977-06-01 1978-07-25 American Cyanamid Company Substituted phenyl naphthalenesulfonic acids
US4132730A (en) * 1977-07-29 1979-01-02 American Cyanamid Company Ureylene naphthalene sulfonic acids
US4120891A (en) * 1977-07-01 1978-10-17 American Cyanamid Company Ureylene naphthalene sulfonic acids
JPS58191772A (ja) * 1982-05-06 1983-11-09 Canon Inc 記録液及びこれを用いたインクジェット記録方法
US4591604A (en) * 1984-03-28 1986-05-27 American Cyanamid Company Method of inhibiting the complement system by administering multisulfonated naphthalene ureas
DE19521589A1 (de) * 1995-06-14 1996-12-19 Bayer Ag Polyfunktionelle Azoreaktivfarbstoffe
EP0960335B1 (en) * 1997-01-15 2005-05-25 Telik, Inc. Modulators of insulin receptor activity
US5830918A (en) * 1997-01-15 1998-11-03 Terrapin Technologies, Inc. Nonpeptide insulin receptor agonists
AU7273598A (en) * 1997-05-05 1998-11-27 Regents Of The University Of California, The Naphthols useful in antiviral methods

Also Published As

Publication number Publication date
KR100746870B1 (ko) 2007-08-07
CZ20014153A3 (cs) 2002-05-15
HUP0201306A2 (en) 2002-09-28
NO20015713D0 (no) 2001-11-23
US7071231B2 (en) 2006-07-04
WO2000071506A3 (en) 2001-08-09
NO20015713L (no) 2001-12-20
EA200101231A1 (ru) 2002-06-27
JP2003500381A (ja) 2003-01-07
CN1364156A (zh) 2002-08-14
AR024109A1 (es) 2002-09-04
NZ515743A (en) 2003-08-29
EA006763B1 (ru) 2006-04-28
HUP0201306A3 (en) 2005-04-28
EP1181271B1 (en) 2005-01-19
DE60017554D1 (de) 2005-02-24
DE60017554T2 (de) 2006-03-30
ZA200109641B (en) 2003-02-24
BR0011550A (pt) 2002-06-04
IL146576A0 (en) 2002-07-25
MXPA01012079A (es) 2003-06-30
UA73738C2 (en) 2005-09-15
AU5168400A (en) 2000-12-12
AU776438B2 (en) 2004-09-09
EP1181271A2 (en) 2002-02-27
US20030135063A1 (en) 2003-07-17
WO2000071506A2 (en) 2000-11-30
WO2000071506A9 (en) 2001-09-20
IL146576A (en) 2006-10-05
ATE287394T1 (de) 2005-02-15
ES2233386T3 (es) 2005-06-16
CA2374225A1 (en) 2000-11-30
KR20020022679A (ko) 2002-03-27
AU776438C (en) 2005-07-28
US6458998B1 (en) 2002-10-01
HK1046399A1 (en) 2003-01-10
TWI234557B (en) 2005-06-21
PL352631A1 (en) 2003-08-25

Similar Documents

Publication Publication Date Title
TR200103409T2 (tr) Glukoz çıkışı arttırıcıları olarak naftalen üreleri.
PT88029A (pt) Processo para a preparacao de derivados piperazinilo de purinas e seus isoesteres uteis como agentes hipoglicemicos
BG105079A (en) Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance
TNSN00206A1 (en) Method for treating diabetes
TWI255817B (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
IL82209A0 (en) Insulin preparation
ATE433959T1 (de) Analoge von kokain
UY26424A1 (es) Método para tratar la diabetes
BR9916279A (pt) Composto, composição farmacêutica, uso de um composto, métodos de tratar ou prevenir doenças do sistema endocrinológico e diabetes melittus não dependente de insulina em um paciente em necessidade deste, e de tratar glicose de resistência prejudicada (ifg) ou tolerância à glicose prejudica (igt) em um paciente em necessida deste, processo para a fabricação de um medicamento particular a ser usado no tratamento ou prevenção de doenças do sistema endocrinológico, e, métodos para preparar os compostos
HUP0001528A2 (hu) Szulfonil-karbamid és glitazon szinergetikus kombinációja diabétesz kezelésére
NO20065904L (no) Terapeutiske forbindelser
BR0016064A (pt) Compostos heterocìclicos e seus sais e uso medicinal dos mesmos
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
DE69322251T2 (de) Medizinische zusammensetzung
CA2344144A1 (en) Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
WO2001060412A3 (en) Modification of biopolymers for improved drug delivery
DK0454783T3 (da) Sted-specifik in vivo aktivering af terapeutiske lægemidler
MXPA03002160A (es) Metodo para el tratamiento de resistencia a insulina en obesidad y diabetes.
WO2004056809A8 (en) Novel piperidine derivatives as modulators of chemokine receptor ccr5
KR960003729A (ko) 항과혈당증 작용을 지닌 약제
NO920855D0 (no) Medikamentinneholdende matrise
ES2166406T3 (es) Uso de derivados de 1,5-benzodiazepina para el control del vaciado gastrico en pacientes con diabetes mellitus no dependiente de insulina.
KR910002456A (ko) 당뇨병 치료용 제약 조성물
EP0324520A3 (en) Alkyl-piperazinyl-5-6-alkylenepyrimidines
GR3001493T3 (en) D-nor-7-ergoline derivatives, process for preparing them, pharmaceutical composition and use